You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AFAP1L2-RET

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Irvine, California
  • +3 more
Aug 30, 2021

Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

Recruiting
  • Non Small Cell Lung Cancer
  • +4 more
  • Irvine, California
  • +15 more
Mar 9, 2022

Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

Active, not recruiting
  • Advanced Nonhaematologic Malignancies
  • Philadelphia, Pennsylvania
  • +20 more
Sep 23, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Advanced Solid Tumor Trial (HEC169096)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Jul 6, 2022

Healthy Trial in Seoul (L04RD1, L04TD2)

Completed
  • Healthy
  • Seoul, Korea, Republic of
    Jaewoo Kim
Jan 10, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Solid Tumor Trial (BS006 Injection)

Not yet recruiting
  • Solid Tumor
  • BS006 Injection
  • (no location specified)
Jul 3, 2023

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Sep 25, 2023

Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT

Recruiting
  • Lung Cancer Stage III
  • Lung Cancer Stage IV
    • Brest, France
      Chu Brest
    Aug 16, 2023

    Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

    Not yet recruiting
    • Metastatic Microsatellite-stable Colorectal Cancer
    • (no location specified)
    Sep 1, 2023

    Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

    Recruiting
    • Biliary Tract Cancer
    • +2 more
    • Shanghai, China
      Zhongshan hospital, Fudan University
    Aug 12, 2023

    Oral Upadacitinib Tablets to Assess Change in Disease Symptoms

    Recruiting
    • Rheumatoid Arthritis (RA)
      • Edmonton, Alberta, Canada
      • +38 more
      Jan 17, 2023

      Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

      Recruiting
      • Metastatic Gastric Cancer
      • +2 more
      • New York, New York
        Bureau for Cancer Research
      May 10, 2023

      HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

      Not yet recruiting
      • HER-2 Positive Advanced Solid Tumors
      • D3L-001
      • (no location specified)
      Jul 20, 2023

      Apnea, Anesthesia, Intubation Complication Trial in Bern (0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust, 2 L/kg/min, FiO2 1.0 +

      Recruiting
      • Apnea
      • +6 more
      • 0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust
      • +2 more
      • Bern, Switzerland
        Department of Anaesthesiology and Pain Medicine, Inselspital, Be
      Jan 15, 2023

      Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

      Recruiting
      • Advanced Solid Tumor
      • Refractory Tumor
      • Radiotherapy
      • +4 more
      • Suzhou, China
        The Second Affiliated Hospital of SchoowUniversity
      Sep 14, 2023

      Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

      Completed
      • Advanced Solid Tumor
      • Inosine 0.2g orally 3 times/day
      • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
      • Beijing, Beijing, China
        Qin li
      Mar 30, 2023

      Brodalumab in Plaque Psoriasis to Understand Impact on Quality

      Recruiting
      • Psoriasis
      • Brodalumab
      • Matched cohort
      • Calgary, Alberta, Canada
      • +33 more
      Oct 8, 2022

      Autosomal Recessive Disorder (Genetic Carriers of PKU) Trial in Guelph (L-Phenylalanine)

      Not yet recruiting
      • Autosomal Recessive Disorder (Genetic Carriers of PKU)
      • L-Phenylalanine
      • Guelph, Ontario, Canada
        University of Guelph
      Oct 31, 2023

      Dementia Trial in Oakville, Toronto (Immersive VR Therapy in Head-Mounted Device (HMD))

      Not yet recruiting
      • Dementia
      • Immersive VR Therapy in Head-Mounted Device (HMD)
      • Oakville, Ontario, Canada
      • +3 more
      May 10, 2023